- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Morgan Stanley startet Coverage für BridgeBio Oncology mit "Overweight"-Rating | 3 | Investing.com Deutsch | ||
| Fr | Morgan Stanley initiates coverage on BridgeBio Oncology stock with Overweight rating | 1 | Investing.com | ||
| 12.11. | BridgeBio Oncology Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.10. | BridgeBio Oncology Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 15.09. | H.C. Wainwright nimmt BridgeBio Oncology mit Kaufempfehlung in die Bewertung auf | 2 | Investing.com Deutsch | ||
| BRIDGEBIO ONCOLOGY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.09. | H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating | 2 | Investing.com | ||
| 04.09. | BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer | 1 | Investing.com | ||
| 04.09. | Oppenheimer stuft BridgeBio Oncology mit "Outperform" ein und sieht erhebliches Kurspotenzial | - | Investing.com Deutsch | ||
| 29.08. | BridgeBio Oncology Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 13.08. | Cantor Fitzgerald startet Coverage für BridgeBio Oncology mit "Overweight"-Rating | 1 | Investing.com Deutsch | ||
| 13.08. | Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating | 1 | Investing.com | ||
| 11.08. | BridgeBio Oncology Therapeutics, Inc. Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition | 126 | GlobeNewswire (Europe) | Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent... ► Artikel lesen | |
| 06.08. | Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics | 314 | GlobeNewswire (Europe) | Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate... ► Artikel lesen | |
| 21.07. | BBOT Appoints Uneek Mehra as Chief Financial Officer | 1 | Contract Pharma | ||
| 11.07. | Helix Acquisition Corp. II shareholders to vote on BridgeBio Oncology merger on August 4 | 20 | Investing.com |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 89,89 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis | Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 68,90 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants | SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,680 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 30,640 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| NUVALENT | 105,74 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| ARCUTIS BIOTHERAPEUTICS | 29,770 | 0,00 % | Amit Munshi joins Arcutis board as founder Chaudhuri retires | ||
| VERA THERAPEUTICS | 44,330 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ENVERIC BIOSCIENCES | 10,360 | 0,00 % | XFRA SLZ0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILENVERIC BIOSCIEN.... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,190 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,35 | 0,00 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| FULCRUM THERAPEUTICS | 13,820 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| ARCELLX | 71,97 | +1,60 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| TREVI THERAPEUTICS | 14,170 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 8,510 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 261,38 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
Das Unternehmen BRIDGEBIO ONCOLOGY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 12,900 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRIDGEBIO ONCOLOGY THERAPEUTICS INC finden Sie auf Wallstreet Online.